Purpura Fulminans – A Rapidly Progressive Coagulopathic Emergency Across The Lifespan
Indunil Karunarathna, Consultant Anaesthetist, Head of the Department, T H Polonnaruwa, Ministry of Health, Sri Lanka, posted on LinkedIn:
”Purpura fulminans is a rare but profoundly life-threatening clinical syndrome characterized by explosive onset of microvascular thrombosis, hemorrhagic infarction of the skin, and, in many cases, disseminated intravascular coagulation. Although it may present in neonates, children, or adults, its pathobiology varies widely according to the underlying mechanism and is classically categorized into neonatal, idiopathic/post-infectious, and acute infectious forms.
Despite distinct etiologies – including genetic deficiencies of natural anticoagulants, autoimmune destruction of protein S, or consumptive coagulopathy in severe sepsis – the final common pathway is a catastrophic imbalance in hemostasis favoring uncontrolled coagulation.
Clinically, patients rapidly progress from erythematous lesions to purpuric patches, hemorrhagic bullae, and full-thickness necrosis, often accompanied by multiorgan dysfunction.
Early recognition, rapid workup for infection and coagulopathy, and immediate initiation of targeted therapy – including anticoagulation, protein C replacement, antimicrobial therapy, immunomodulation, and surgical debridement – are essential to improve survival.
Although modern intensive care has reduced mortality, survivors frequently experience permanent disability, making purpura fulminans a condition that demands high clinical vigilance and an integrated, multidisciplinary response.”
Read the full article here.
Title: Purpura Fulminans A Rapidly Progressive Coagulopathic Emergency Across The Lifespan
Author: Indunil Karunarathna
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS